Our GHG emissions across the value chain

Our total emissions: 6.6 million tCO_2e

	Upstream	Our operational GHG footprint			Downstream
Where our emissions occur	**Upstream production and R&D at non-AstraZeneca sites**	**Outsourced supply of API, F&P and transportation**	**Our sites and fleet**	**Site waste incineration and customer use**	**End-of-life for packaging and patient travel**
Percentage of total tCO_2 emissions*	61% Scope 3	5% Scope 3	7% Scopes 1 and 2	13% Scope 3	14% Scope 3
How we're working to reduce GHG emissions	**Working with suppliers including:** Assessing data to understand the wider impact Identifying emissions hotspots through LCAs	**Energy efficiencies including:** Collaborating with peers on a supplier environmental data platform Switching from air to sea freight Enabling virtual conferencing	**Investing in our sites and fleet including:** Using 100% renewable power on all our sites by 2025 Funding resource efficient capital projects	**Product and process advancements including:** Researching alternative propellants for pressurised metered dose inhaler therapies Investing in hazardous waste reduction	**Product and packaging advancements including:** Designing waste out of our packaging Enabling better adherence to reduce patient travel